Lunit Publishes Study Showing AI’s Ability to Improve Breast Cancer Detection
The prospective study reportedly showed an improvement of over 10%.
Stock.adobe.com
Lunit announced the results of a prospective study that looked into the usage of AI in mammography screening.1 According to the results, the powerful technology improves the detection rates for breast cancer without increasing recall rates. In a press release, Lunit states that AI improved the detection rates by 13.8%.
The study’s lead and corresponding author Professor Chang explained, “This prospective study offers compelling real-world evidence that AI can improve early cancer detection while maintaining effectiveness and reducing unnecessary patient anxiety caused by false positives in a single-reading setting.”
Lunit is an AI company that develops solutions for cancer diagnostics and therapeutics.
In the same press release, Lunit’s CEO Brandon Suh said, “This latest prospective study in South Korea further solidifies Lunit INSIGHT MMG's potential as an indispensable tool in breast cancer screening. Whether in a single-reader or double-reader setting, AI can serve as a powerful force multiplier, assisting radiologists in detecting cancer earlier and more accurately."
Suh continued, “As AI adoption accelerates, we remain committed to driving innovation and making AI-powered cancer screening the new standard of care," added Suh. "By working closely with healthcare providers worldwide, we aim to ensure that AI benefits as many patients as possible."
Lunit also recently announced that it has reached a new agreement with Cloud Solutions, part of Saudi Arabia’s largest medical group, to supply it’s AI-powered X-ray analysis solution to the region for the next three years.2 The two organizations had previously collaborated in 2023.
In a press release, Suh said, “We are proud to further strengthen our collaboration with Dr. Sulaiman Al Habib Medical Group. This second contract underscores the value of our AI solutions and reflects our shared commitment to advancing healthcare through innovation."
Suh continued, “Expanding our partnership with HMG demonstrates the growing demand for AI-powered diagnostics across the Middle East. We are excited to continue supporting Saudi Arabia's healthcare transformation while addressing key challenges such as radiologist shortages."
Lunit also recently announced the appointment of Craig Hadfield as CEO of one its subsidiaries, Volpara Health Technologies.3 In a press release, Suh said, “We are confident that Craig's leadership will drive Volpara's continued success and innovation in breast health. His deep understanding of Volpara's business and his proven leadership make him the ideal person to guide the company into its next phase of growth. We look forward to his continued success in driving Volpara's mission to advance breast health solutions worldwide."
In the same press release, Hadfield added, “I am honored to step into this role and continue leading Volpara's mission to transform breast health through innovative AI-powered solutions. Having been part of Volpara's journey for nearly a decade, I look forward to working with our talented team, partners, and customers to expand our impact and drive even greater value in breast cancer detection and patient care."
Sources
- World's First Large-Scale, Multicenter Prospective Study in Single-Reading Mammography Confirms Lunit AI Boosts Cancer Detection. Lunit. March 10, 2025. https://www.prnewswire.com/news-releases/worlds-first-large-scale-multicenter-prospective-study-in-single-reading-mammography-confirms-lunit-ai-boosts-cancer-detection-302395506.html
- Lunit Expands Partnership with Saudi Arabia's Largest Medical Group to Deploy AI Chest X-Ray Solution. Lunit. March 6, 2025. https://www.prnewswire.com/news-releases/lunit-expands-partnership-with-saudi-arabias-largest-medical-group-to-deploy-ai-chest-x-ray-solution-302394656.html
- Lunit Announces Leadership Transition at Volpara: Craig Hadfield Appointed CEO. Lunit. February 26, 2025. Accessed March 10, 2025. https://www.prnewswire.com/news-releases/lunit-announces-leadership-transition-at-volpara-craig-hadfield-appointed-ceo-302385666.html
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
